The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
about
Is NF-kappaB a good target for cancer therapy? Hopes and pitfallsEGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatmentWhy bortezomib cannot go with 'green'?Multiple myelomaSeliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myelomaAzaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoThe proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyRegulation of IkappaBalpha expression involves both NF-kappaB and the MAP kinase signaling pathways.Maintaining Genome Stability in Defiance of Mitotic DNA DamageRedox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and TherapySalvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Current Trends of Renal Impairment in Multiple MyelomaDrugging the undruggables: exploring the ubiquitin system for drug developmentNovel strategies to target the ubiquitin proteasome system in multiple myelomaDangER: protein ovERload. Targeting protein degradation to treat myelomaAdvances in the understanding of mechanisms and therapeutic use of bortezomibA novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic diseaseCharacterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunitIncorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like SitesLoss of a 20S proteasome activator in Saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of actionClinical use of proteasome inhibitors in the treatment of multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyTargeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein HomeostasisTargeting NF-kappaB in Waldenstrom macroglobulinemiaControl of Kaposi's sarcoma-associated herpesvirus reactivation induced by multiple signalsSmall compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myelomaTherapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC)Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cellsCharacterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell deathPI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cellsFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentTargeting neuroblastoma stem cells with retinoic acid and proteasome inhibitorEx-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapyInhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737Progressively impaired proteasomal capacity during terminal plasma cell differentiation.Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells.Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma
P2860
Q24570128-FD5D8758-4966-4E2C-B6F1-52236668A606Q24616455-17C6E192-6FE3-439B-840B-61132FAA3E63Q24630709-021BBD6D-A186-4002-A019-D7829E2BB2EBQ24655964-1C76D0DA-EF6E-4FD6-B742-6C6A6D4176A6Q24669938-4300E5E5-2C7C-4659-AE4C-52FBD1969607Q24670297-1AD81A74-8E95-49E3-9F73-138FCE23AB31Q24813108-7F792A93-E11D-440B-825E-B8FF0E8DD7CDQ24814325-C5C3B571-02C0-4B85-B98C-28586D1F1CF3Q24815441-1FFFEFA0-B685-42D4-AA5D-D0AC0778B25EQ26738970-D18F7EFA-4987-4382-B743-2C5B8BB1D980Q26740191-8656A0ED-F439-4B5D-B83E-3BEBF9981717Q26740359-5309CCA1-858B-4598-B569-4A1AD06AE16CQ26740444-F068AC62-C8C4-4AAE-979D-61F6F0540DC4Q26752823-608BB621-D9A3-4A4B-9974-31BDFED101FDQ26773246-D9044E9D-FD78-43E9-9FB9-DCAF4555A0A1Q26825417-5847A529-618F-4857-AE9B-500264587A00Q26849940-F96BDAB2-CD20-4943-B7E3-F1EB168B36ACQ27329429-7ED435BD-81E9-4A3D-B6DA-4E93AEF4704FQ27663486-17E2E4D9-0577-474B-A8B9-20B5D8550819Q27675903-D7AA1F6B-B7EE-48F6-8DB7-9BE0168CCC52Q27930325-D91BA9B4-C13E-4B56-8B99-A624D5D2B655Q28080999-ACDA4A95-F49B-4CEA-AD13-25AC565FAB7EQ28082910-2AE1FFC1-9E8F-4019-9D5C-ED7E0B080FB8Q28269674-2B120EBA-25F4-4DEE-BA3A-5318CB34ADE6Q28272373-07AEE34A-8084-4AFB-983B-9D8B347E6490Q28478842-77261382-0D45-43B7-952D-9C8F124310FAQ28478936-8FE9CE65-0614-449E-9CAE-1D69D137C910Q28481010-4B9A8487-514A-49CA-AA54-748518A1FC0CQ28481321-25FF9570-F8E3-4E50-A03C-77F369FC6D4AQ28482928-59755C55-8245-4427-AA7B-12F9119BCEAFQ28484680-4ACF3A24-D81A-45C3-9869-9E8DACD9819FQ28533949-D6D2E51A-64D8-4F68-B3B4-1FAB6D9F1559Q28534151-FDB38E27-0A8F-408E-BC5F-3A4AC1E0580AQ28535634-B43A9D2A-78E1-42B1-8870-BA8638B2702AQ28542684-E89618D0-CECC-4D51-9C90-34CFF8DD2FB3Q30476988-A969661D-5793-4136-A08A-D71CBE81D6B9Q30952817-16E1079F-A10C-4482-BF53-E297E89E3BB7Q31028788-F9ABFBF5-9322-4C7D-921E-41499F64762CQ33289791-27984C3A-8B02-408B-A90F-C05EED2D5998Q33367833-283FDC0B-C5F1-4747-81DC-8AC0A47D0612
P2860
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The proteasome inhibitor PS-34 ...... human multiple myeloma cells.
@ast
The proteasome inhibitor PS-34 ...... human multiple myeloma cells.
@en
The proteasome inhibitor PS-34 ...... human multiple myeloma cells.
@nl
type
label
The proteasome inhibitor PS-34 ...... human multiple myeloma cells.
@ast
The proteasome inhibitor PS-34 ...... human multiple myeloma cells.
@en
The proteasome inhibitor PS-34 ...... human multiple myeloma cells.
@nl
prefLabel
The proteasome inhibitor PS-34 ...... human multiple myeloma cells.
@ast
The proteasome inhibitor PS-34 ...... human multiple myeloma cells.
@en
The proteasome inhibitor PS-34 ...... human multiple myeloma cells.
@nl
P2093
P1433
P1476
The proteasome inhibitor PS-34 ...... n human multiple myeloma cells
@en
P2093
K C Anderson
P J Elliott
P Richardson
T Hideshima
V J Palombella
P304
P407
P577
2001-04-01T00:00:00Z